HSBC analyst Rajesh Kumar raised the firm’s price target on Pfizer (PFE) to $29 from $28 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, “even more so if AI panic kicks in.” HSBC’s preferred stocks are “growth bucket ideas,” but says “fallen angels and value could work as well.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk
- FDA probe into COVID vaccines includes adults, Bloomberg reports
- FDA to investigate COVID vaccine safety across age groups
- Pfizer’s Fosun-partnered GLP-1 drug more aligned with orforglipron, Leerink says
- Pfizer signs exclusive collaboration and license agreement with YaoPharma